Table 1 Baseline characteristics of the patients
Avacopan (n = 21) | |
|---|---|
Age, years | 77 (66–81) |
Male sex, n (%) | 11 (52.4%) |
Body weight, kg | 53 (47–62) |
BMI, kg/m2 | 21.2 (19.1–24.4) |
eGFR, mL/min/1.73 m2 | 43 (35–51) |
Serum albumin, mg/dL | 3.2 (2.6–4.0) |
CRP level, mg/dL | 2.3 (0.5–8.2) |
Type of ANCA-associated vasculitis | |
GPA | 3 (14.3%) |
MPA | 18 (85.7%) |
ANCA-associated vasculitis status | |
Newly diagnosed | 18 (85.7%) |
Relapsed | 3 (14.3%) |
ANCA positivity | |
PR3-ANCA positive | 2 (9.5%) |
MPO-ANCA positive | 18 (85.7%) |
ANCA-negative | 1 (4.8%) |
BVAS | 14 (13–17) |
Organ involvement | |
General | 19 (90.4%) |
Cutaneous | 1 (4.7%) |
Ear, nose, and throat | 3 (14.3%) |
Pulmonary | 11 (52.4%) |
Diffuse alveolar haemorrhage | 0 |
Interstitial lung diseases | 9 (42.9%) |
Nodules | 2 (9.5%) |
Heart | 0 |
Abdominal | 0 |
Nervous system | 6 (28.6%) |
Kidney | 15 (71.4%) |
Haematuria | 15 (71.4%) |
Proteinuria (g/gCr) | 0.6 (0.3–1.2) |
Rapidly progressive glomerulonephritis | 5 (23.8%) |